Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma - Wikidata - wikimedia - TriplyDB

Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma

Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma

http://www.wikidata.org/entity/Q35202400

about

Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians Adjuvant therapy for pancreas cancer in an era of value based cancer care Management of borderline resectable pancreatic cancer Advances of stereotactic body radiotherapy in pancreatic cancer A current perspective on stereotactic body radiation therapy for pancreatic cancer A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review.Stereotactic body radiation therapy for patients with recurrent pancreatic adenocarcinoma at the abdominal lymph nodes or postoperative stump including pancreatic stump and other stump.Quantification of renal function following stereotactic body radiotherapy for pancreatic cancer: secondary dosimetric analysis of a prospective clinical trial.An unusual genomic variant of pancreatic ductal adenocarcinoma with an indolent clinical course.Modeling Combined Chemotherapy and Particle Therapy for Locally Advanced Pancreatic Cancer A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol.Pancreatic cancer and SBRT: A new potential option?Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing: Implications for Surgical Management Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer.Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance.A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma.Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer.Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial: study design and rationale of a phase II clinical Increased serum levels of betatrophin in pancreatic cancer-associated diabetes Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas.The role of neoadjuvant therapy in pancreatic cancer: a review.Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions.Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer.Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer : Literature review and practice recommendations of the DEGRO Working Group on Stereotactic Radiotherapy.Having Your Cake and Eating It Too: Combining SBRT and Multi-agent Chemotherapy in Locally Advanced Pancreatic Cancer.The development of stereotactic body radiotherapy in the past decade: a global perspective.Dose escalation study with respiratory-gated carbon-ion scanning radiotherapy using a simultaneous integrated boost for pancreatic cancer: simulation with four-dimensional computed tomography.Systematic Review and Case Series Report of Acinar Cell Carcinoma of the Pancreas.Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer.Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer : A toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT.The Role of Consolidation Chemo-Radiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Systematic Review and Meta-Analysis.Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer.Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer.Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma Reirradiation with stereotactic body radiation therapy after prior conventional fractionation radiation for locally recurrent pancreatic adenocarcinoma.

P2860

Q26747145-706A31F0-7DA5-47D4-B26F-8C98D2F5364A Q26767041-CA66F53A-48F2-44AD-9659-B6C8A9EF923B Q26775916-FDF58BAE-5B27-4D4F-AE2A-CDC3E48F0AA3 Q26781445-71CC8AE9-EF2F-4EF1-B1F2-305565ECEA35 Q26781550-B39D7940-D2A6-4570-80F3-0BF673DBB272 Q28077111-B6F1DB86-C7BE-4D55-977F-F2EE206A9983 Q30238706-41080559-DE35-46F5-AD14-1EF3B50475FC Q33433915-6149491D-6337-48FA-90DB-7588871433F1 Q33612704-B11D8A19-4669-49D4-9164-7D141FD27BB4 Q33865090-5C9D0DD3-2B27-4B08-9F37-653E22929267 Q35820403-60EC673B-B4A5-43EE-AB36-C4592F039826 Q36130588-F02755B3-3CA4-4C39-9891-25C9C7E7B945 Q36133787-BFA26699-583E-4A03-A0AC-0878F75D6817 Q36326886-1EA6A566-FC77-46DF-BECA-1D0642DAFC55 Q36666622-01E16002-4F66-4B2A-9350-5DC8FC4AF443 Q36747321-EB7A9FFE-D44F-4C8B-BA2A-A79DAD55342F Q36842981-EACA80A7-34E1-4E39-8196-42938C39C1C3 Q37013991-7123D025-DD89-4822-A9F5-F14FF22FEC90 Q37178662-36A442C2-AAAF-49DE-9D69-22EC4E568E99 Q37401414-ECE974AE-8C66-4BE1-9A64-5A8AC0F5A9D6 Q37517051-44F4DB60-FAA3-409A-9248-F9ACCC5FDBF9 Q37520539-6EFCFE28-69E0-4F7F-B34E-457A614C1E74 Q38650842-6D0107CD-BCDE-4528-AD06-4232F4148A8F Q38734981-DB3E7250-C9AC-4BF1-AA3D-5995E447A33C Q38783194-6C8A569F-7BDD-451C-8AF7-3F4D0E2DDF02 Q38792423-7AE7F203-EC1E-4DE3-B7F5-2D157AEE3716 Q38794011-536663ED-8EBF-420F-BF9C-772461E9F9A2 Q38806110-2A843327-3476-4D1F-B7EF-6336203A1BE5 Q38935821-5DAC2360-49B0-4C2C-97A1-02139FDA3506 Q38967475-4A0FFCB4-7B6C-468F-995F-45ED15AE3364 Q38970133-E4714AFC-F63C-4C75-A948-159B77164AF8 Q39008039-1BEFCCD0-1C07-47E6-B92D-89BD1081A491 Q39065321-94F90DB9-1316-4769-9EDC-A88D7B969D02 Q39110839-0F0D78A8-99BE-471D-9689-8918CD3DCE3E Q39364761-CA8E2DA6-7794-4251-9477-7A27F23B114F Q39462375-A4E34C50-45B2-4923-99D7-1CBF4BC58C95 Q40141235-E93E20B2-FA1C-4A11-A26A-AF2B96ABDC69 Q40975780-B0E0C943-AD88-4A78-A403-B23478517C2F Q41039645-B0639E50-24A1-40F5-A92B-AE8E461AA472 Q41039836-F4C3E7B4-92F6-4D34-A225-03D627836D14

P2860

Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma

http://www.wikidata.org/entity/Q35202400

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Phase 2 multi-institutional tr ...... able pancreatic adenocarcinoma

@ast

Phase 2 multi-institutional tr ...... able pancreatic adenocarcinoma

@en

type

label

Phase 2 multi-institutional tr ...... able pancreatic adenocarcinoma

@ast

Phase 2 multi-institutional tr ...... able pancreatic adenocarcinoma

@en

prefLabel

Phase 2 multi-institutional tr ...... able pancreatic adenocarcinoma

@ast

Phase 2 multi-institutional tr ...... able pancreatic adenocarcinoma

@en

P1433

Q35202400-3FDE9B3F-37C0-474C-A485-14CB801039AD

P1476

Q35202400-234C1536-0996-4DB0-95AC-B8E6D035DA2E

P2093

Q35202400-10B8407B-0B0E-4F36-8D11-E6E267F4F482

Q35202400-22DBF473-1878-4643-8F30-57B2D995A2C7

Q35202400-428407A8-D9C7-4AE5-A8BD-648198F9F7C5

Q35202400-44DB0399-8C73-46E0-872D-AB6B28558F65

Q35202400-47C3C63B-FE3A-47CF-A6AA-E02448C14084

Q35202400-4E55FBB9-A8C9-430A-B9D3-3BA384B7CF14

Q35202400-5216D714-75FB-4081-923A-AD28FECE70B4

Q35202400-53985727-DAA6-4B0A-824E-635987FA426D

Q35202400-5907DE83-6326-4A86-831D-73C2BD9436D9

Q35202400-7EC95DFB-09B8-4C31-B73D-AD9B069C4CED

P2860

Q35202400-0A2464DC-8637-4A28-AFDF-14C246D4D45F

Q35202400-15F4D06C-70C0-42FD-9A29-99DE771F0440

Q35202400-1D45F384-7FC5-4C68-B2FA-417D96E6A874

Q35202400-2DF65FE7-3701-4AD3-BDAA-ADE732A343D1

Q35202400-5A3CF8F5-C379-4B91-BB86-2C5C0EAE034D

Q35202400-5AF7EDEB-8FB2-4F22-BDD3-1D521BCA27B3

Q35202400-5C3EDE46-39B0-4EFA-9AEF-B186C119220B

Q35202400-5F09347F-3B29-4AD8-920C-C948D5C9605F

Q35202400-5F1052C1-D94E-4C6D-B67B-41F466E5A0A9

Q35202400-627CA37F-1BCB-4379-9D8F-841E8AB005F9

P304

Q35202400-A007AE7E-3E0E-435B-ACBB-E0B4B1478C3D

P31

Q35202400-3E8B264F-024E-4AFB-9D50-549C154CDBD3

P356

Q35202400-72E2507A-628E-4BCF-AF37-EF51049F1AE1

P407

Q35202400-28F5C394-8141-47B5-895F-F543D5493FAB

P433

Q35202400-E48EB0AA-B828-47C3-8BE3-7EFC72266F21

P478

Q35202400-3EC65EB5-C50F-4CA8-92F2-0E8E917A5520

P50

Q35202400-51AF2C62-41C7-40B5-8DF0-7C87D3587CF3

Q35202400-CF77589D-F64F-43FC-925E-277D4489B3F3

P577

Q35202400-7DC192A4-26B0-46D8-9B21-B337E26A080D

P5875

Q35202400-1D1B1D7A-1B55-439B-B363-E12B0EF1C1CF

P698

Q35202400-0FAA3B59-4B2D-4C0E-AA01-A6C3F53C4166

P921

Q35202400-23C36782-E403-4BEA-B3E2-6AF4F95DC91C

Q35202400-7CC393BC-2D8B-453E-8C93-258182B63A12

Q35202400-93466963-1A8C-42FF-A074-A293D94A6C39

P932

Q35202400-A0EA668F-473F-4721-AF14-DEA20CA0C466

P356

P1433

P1476

Phase 2 multi-institutional tr ...... able pancreatic adenocarcinoma

@en

P2093

Aaron T Wild

http://www.w3.org/2001/XMLSchema#string

Albert C Koong

http://www.w3.org/2001/XMLSchema#string

Amy Hacker-Prietz

http://www.w3.org/2001/XMLSchema#string

Avani S Dholakia

http://www.w3.org/2001/XMLSchema#string

Christopher L Wolfgang

http://www.w3.org/2001/XMLSchema#string

Daniel A Laheru

http://www.w3.org/2001/XMLSchema#string

Daniel T Chang

http://www.w3.org/2001/XMLSchema#string

Eileen O'Reilly

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Sugar

http://www.w3.org/2001/XMLSchema#string

George A Fisher

http://www.w3.org/2001/XMLSchema#string

P2860

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

Cancer statistics, 2012

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer

Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.

Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas

Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.

Comparative analysis of traditional and coiled fiducials implanted during EUS for pancreatic cancer patients receiving stereotactic body radiation therapy

P304

1128-1137

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.29161

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P50

Christine A Iacobuzio-Donahue

P577

2014-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270004004

http://www.w3.org/2001/XMLSchema#string

P698

25538019

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

phase II clinical trial

P932

4368473

http://www.w3.org/2001/XMLSchema#string